ScholarLens Back to search
2020•Journal of Medicinal ChemistryOpen access

Synthetic Lethality in Pancreatic Cancer: Discovery of a New RAD51-BRCA2 Small Molecule Disruptor That Inhibits Homologous Recombination and Synergizes with Olaparib

Greta Bagnolini, Domenico Milano, Marcella Manerba, Fabrizio Schipani, Jose Antonio Ortega, Dario Gioia, Federico Falchi, Andrea Balboni, Fulvia Farabegoli, Francesca Franco, Janet Robertson, Roberto Pellicciari, Isabella Pallavicini, Sebastiano Peri, Saverio Minucci, Stefania Girotto, Giuseppina Di Stefano, Marinella Roberti, Andrea Cavalli

Open full text 53 citations

Abstract

-competent and olaparib-resistant cancers, making fully small-molecule-induced synthetic lethality an innovative approach toward unmet oncological needs.

Open-access reader

About this research paper

What this paper is about

-competent and olaparib-resistant cancers, making fully small-molecule-induced synthetic lethality an innovative approach toward unmet oncological needs.

Why it matters

OpenAlex reports 53 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

-competent and olaparib-resistant cancers, making fully small-molecule-induced synthetic lethality an innovative approach toward unmet oncological needs.

Key concepts: Olaparib, Synthetic lethality, Homologous recombination, RAD51, Lethality, Cancer research, Small molecule, Pancreatic cancer

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Synthetic Lethality in Pancreatic Cancer: Discovery of a New RAD51-BRCA2 Small Molecule Disruptor That Inhibits Homologous Recombination and Synergizes with Olaparib — Research Paper | ScholarLens